Abstract:KRAS, a predominant member of the RAS family, is the most frequently mutated oncogene in human pancreatic cancer (∼95% of cases). Mutations in KRAS lead to its constitutive activation and activation of its downstream signaling pathways such as RAF/MEK/ERK and PI3K/AKT/mTOR that promote cell proliferation and provide apoptosis evasion capabilities to cancer cells. KRAS had been considered 'undruggable' until the discovery of the first covalent inhibitor targeting the G12C mutation. While G12C mutations are frequently found in non-small cell lung cancer, these are relatively rare in pancreatic cancer. On the other hand, pancreatic cancer harbors other KRAS mutations such as G12D and G12V. The inhibitors targeting G12D mutation (such as MRTX1133) have been recently developed, whereas those targeting other mutations are still lacking. Unfortunately, KRAS inhibitor monotherapy-associated resistance hinders their therapeutic efficacy. Therefore, various combination strategies have been tested and some yielded promising results, such as combinations with receptor tyrosine kinase, SHP2, or SOS1 inhibitors. In addition, we recently demonstrated that the combination of sotorasib with DT2216 (a BCL-XL-selective degrader) synergistically inhibits G12C-mutated pancreatic cancer cell growth in vitro and in vivo. This is in part because KRAS-targeted therapies induce cell cycle arrest and cellular senescence, which contributes to therapeutic resistance, while their combination with DT2216 can more effectively induce apoptosis. Similar combination strategies may also work for G12D inhibitors in pancreatic cancer. This chapter will review KRAS biochemistry, signaling pathways, different mutations, emerging KRAS-targeted therapies, and combination strategies. Finally, we discuss challenges associated with KRAS targeting and future directions, emphasizing pancreatic cancer.

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment

Targeting KRAS in PDAC: A New Way to Cure It?

Targeting KRAS in pancreatic cancer

Abstract IA-05: Targeting KRAS for pancreatic cancer treatment

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?

Targeting KRAS in cancer

Kras as a key oncogene and therapeutic target in pancreatic cancer

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells

Research progress of KRAS-targeted therapy for pancreatic ductal adenocarcinama

KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer

KRAS mutation: from undruggable to druggable in cancer

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants